Compare PIII & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PIII | CODX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 15.6M |
| IPO Year | N/A | 2017 |
| Metric | PIII | CODX |
|---|---|---|
| Price | $5.30 | $0.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $16.25 | $2.25 |
| AVG Volume (30 Days) | 9.8K | ★ 2.1M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,444,952,000.00 | $507,892.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.45 | $31.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.97 | $0.23 |
| 52 Week High | $14.50 | $1.55 |
| Indicator | PIII | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 29.58 | 51.18 |
| Support Level | $5.14 | $0.34 |
| Resistance Level | $5.62 | $0.42 |
| Average True Range (ATR) | 0.48 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 9.86 | 72.45 |
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.